Non-Antibiotic Antimicrobial Catheter Lock Solutions in Patients on Home Parenteral Nutrition

Jessica Noelting 1, Brian Jurewitsch 2 and Johane P. Allard 3,*  
1 Division of Gastroenterology & Gastrointestinal Diseases Research Unit, Queen’s University, Kingston, ON K7L 2V7, Canada; jessica.noelting@kingstonhsc.ca  
2 Specialized Complex Care Program, St. Michael’s Hospital, Faculty of Pharmacy, University of Toronto, Toronto, ON M5B 1W8, Canada; Brian.Jurewitsch@utoronto.ca  
3 Division of Gastroenterology, University of Toronto, Toronto, ON M5G 2C4, Canada  
* Correspondence: johane.allard@uhn.on.ca; Tel.: +1-416-340-4800 (ext. 5159)

Received: 30 July 2018; Accepted: 22 August 2018; Published: 25 August 2018

Abstract: Patients on home parenteral nutrition (HPN) are dependent on central venous access for long-term sustenance, and catheter-related bloodstream infections (CRBSIs) are a major cause of morbidity and mortality in this patient population. As such, there is much interest in finding new methods for preventing CRBSIs in patients on HPN. As it is thought that these infections are preceded by microbial colonization of the catheter, one approach is to use antimicrobial catheter lock solutions. Although antibiotic catheter lock solutions have been present for decades, their use has been mostly limited to the treatment of CRBSIs due to concern for promoting microbial resistance. Recently, however, with the advent of non-antibiotic antimicrobial catheter lock solutions, this approach is gaining popularity as a promising method to decrease rates of CRBSI in HPN patients.

Keywords: central venous catheter; parenteral nutrition; catheter-related infections; anti-bacterial agents

1. Introduction

Parenteral nutrition is a life-sustaining therapy required in patients who do not have a functioning gastrointestinal tract. This can be either second to surgical removal, or malfunction (such as in malabsorptive conditions and dysmotility). The intravenous provision of nutrition requires central venous access so that a hyperosmolar nutrient solution can be infused. A variety of central venous catheters (CVCs) can be used, including peripherally inserted central catheters (PICCs), tunneled catheters, and implanted ports. The most common complication, and most frequent cause of hospitalization in patients on home parenteral nutrition (HPN) is bloodstream infection [1]. Additionally, repeated infections and replacement of venous access catheters can lead to complications such as the loss of vascular access sites. Therefore, many efforts have been made to reduce the risk of catheter-related bloodstream infections (CRBSIs) including: education in aseptic technique, application of topical antimicrobial agents to the exit site, and reducing the number of manipulations of the catheter and solutions for infusion. Although antimicrobial catheter lock solutions have been used for many years, they were traditionally composed of antibiotics, and due to concern for promoting antibiotic resistant microorganisms, their use was restricted to treatment of infections. Antimicrobial catheter lock solutions are also used in hemodialysis catheters [2] but reviewing this is beyond the scope of this paper.

The aim of this scoping review is to discuss the various non-antibiotic catheter lock solutions, their potential role for CRBSI prophylaxis in HPN patients and to identify the need for further research in this area.
2. Non-Antibiotic Antimicrobial Catheter Lock Solutions

2.1. Citrate

Citrate has been successfully used for prevention of thrombosis and CRBSI in dialysis catheters [3]. However, this included citrate in combination with other microbial agents. When evaluating citrate alone, it was not better than heparin for prevention of CRBSI at concentrations up to 4% [3,4]. Only one trial showed that it may have antimicrobial effects, but this was with much higher concentration of 30% [5]. Although citrate alone as a catheter lock solution has not been evaluated in HPN patients, it is frequently combined with other agents. Citrate is thought to have anticoagulant activity and to reduce biofilm, which can aid with the penetration of other antimicrobial agents. The mechanism of action of citrate is related to calcium chelating properties. However, this has also led to concerns regarding the safety of citrate in high concentrations due to the risk of hypocalcemia and risk of bleeding, and it is generally recommended to use a maximum concentration of 4% citrate for catheter lock solutions and to attempt as close a match as possible between the volume of the citrate with that of the catheter. In general, there is some 15% of overspill of citrate into the circulation at time of instillation which may account for why patients may report immediate sensations depending on the concentration [6,7]. It is prudent for these patients to aspirate the lock at the end of the dwell time; however, fibrin sheath formation at the tip of the catheter and obscuring the lumen may function as a one-way valve not permitting aspiration/blood return, leaving slow flushing as the only option in reaccessing the line.

2.2. Ethanol

Ethanol, in various concentrations, has been successfully used to prevent and treat CRBSI in HPN patients. There have been many studies showing the value of ethanol lock therapy (ELT) in pediatric patients on HPN, including a meta-analysis combining nine studies of patients with intestinal failure that showed 6.27 fewer events per 1000 catheter days in patients using ELT compared to heparin [8,9]. In a retrospective review of 31 adult HPN patients with tunneled silicon catheters and a history of CRBSI, the rates of CRBSI decreased from 3.53 to 1.65 per 1000 catheter days after initiation of ELT [10]. In that study, patients locked each lumen of their catheter with a 70% ethanol solution after each infusion, and then flushed their catheter with normal saline prior to the next. In another study using this same solution and lock/flush protocol, there was a decreased rate of CRBSI from 4.18 to 0.47 per 1000 catheter days in eight adult HPN patients with single-lumen tunneled catheters made from polyurethane [11]. Although ethanol lock solutions have shown promise in reducing CRBSI, their use has been limited due to higher rates of mechanical complications such as occlusion and disrupted integrity of the catheter, requiring increased catheter replacement [9,12,13]. There is also concern regarding the potential for inebriation with flushing concentrated ethanol into a central vein. General application of ELT for HPN patients in the United States, for example, is also limited by the fact that it does not have the indication for locking catheters from the Food and Drug Administration, making it an off-label use.

2.3. Taurolidine

Taurolidine is a derivative of taurine, an amino acid; it degrades into taurine, carbon dioxide and water. It is a bactericidal agent that is effective against gram positive and gram negative organisms, as well as some fungi [4]. There have been many studies showing the effectiveness of taurolidine lock solution for secondary prophylaxis of CRBSI [14–21]. However, as described in meta-analyses, most of these studies are limited by methodology (observational) and small sample size [22]. There are two randomized controlled trials, which will be reviewed here. The first is a randomized, placebo-controlled, double blind study of 41 patients (21 heparin, 20 taurolidine) [19]. In this study, a solution containing taurolidine 1.35%, sodium-citrate 4%, and heparin 100 IU/mL was used, and only patients with a previous CRBSI in the last 4 years and a tunneled catheter were included. None of the patients in the taurolidine arm experienced a CRBSI during the total 9622
catheter days, as compared to seven CRBSIs in the heparin arm during a total of 6956 catheter days. Although there were seven positive blood cultures in the taurolidine group, these were either not treated, or another source of infection was found and treated. Despite the small number of patients in this study, there was a significant reduction in CRBSIs (p = 0.0052) in patients receiving taurolidine compared to heparin, without a difference in occurrence of mechanical complications. The second is a multi-center randomized, double-blinded study comparing 2% taurolidine to 0.9% saline in 102 patients from five countries [21]. They included two groups of patients: 71 patients with new central venous catheter and 31 patients which they called ‘high-risk’, defined as having a pre-existing central venous catheter in place for at least 6 months prior to enrollment, on HPN for at least one year and a CRBSI rate of at least 0.82 per 1000 catheter days. They showed that taurolidine significantly decreased rates of CRBSI per thousand catheter days in the new catheter group (0.29 versus 1.49) and in the combined group (0.33 versus 1.44) (p = 0.002). Although the rate of CRBSI was also decreased in the high-risk group, this was not statistically significant, possibly due to the small number of patients in that group. However, it is also possible that there was already a biofilm present in those patients’ catheters and that taurolidine was not effective in that setting. Additionally, some of the catheters could have been subjected to salvage protocols with antibiotics having been both intraluminally applied as a lock and intermittently infused to treat with the result of residual high colony counts left in the biofilm, outstripping the effect of the taurolidine over time, although this detail is not disclosed. Forty-four out of 71 new catheter patients had never had a CRBSI prior to enrollment, and, in these patients, none of those randomized to taurolidine experienced a CRBSI, compared to nine of those in the saline arm. It is also notable that, in this study, there was no difference in catheter occlusion rate or patient satisfaction between saline and taurolidine. There is only one study that aimed to assess the use of taurolidine in patients with a low rate of CRBSI (defined as less than one CRBSI per patient per year) [23]. Unfortunately, with only 30 patients followed for one year, divided between three different catheter lock solutions (taurolidine 2%, taurolidine 1.34% with citrate and saline), this study was likely underpowered to demonstrate any difference between the three catheter lock solutions. There are different taurolidine catheter lock solutions used in various studies including either heparin and/or citrate in addition to taurolidine, and with taurolidine concentrations ranging from 1.34% to 2%. However, an in vitro analysis of different taurolidine solutions did successfully inhibit the growth of microbial pathogens [4], and although the microbicidal effect of taurolidine was greater at higher concentration (2% versus 1.34%), the clinical significance of this is not known. This study also demonstrated that the combination of taurolidine with heparin and/or citrate did not affect its antimicrobial effect. As it is not an antibiotic, one would not expect antimicrobial resistance to develop. Accordingly, a study from the Netherlands using 27 study isolates from 9 patients who developed CRBSIs while using taurolidine lock solution did not find any microbial adaptation of microorganisms to taurolidine [24].

2.4. Tetrasodium Ethylenediamine Tetraacetic Acid (EDTA)

The tetrasodium EDTA catheter lock solution has been shown to reduce biofilm formation and bacterial colonization [25,26]. Furthermore, EDTA is a known anticoagulant and it is used in blood collection tubes because of this property [27]. The tetrasodium EDTA lock solution has been safely used in hemodialysis catheters [26]; however, there are no published studies of the tetrasodium EDTA catheter lock solution in patients on home PN.

3. The Canadian Experience

Currently, patients on home PN in several programs in Canada do not use an antimicrobial catheter lock solution unless they have recurrent (more than one) CRBSIs. In Canada, Taurolidine is currently only approved for investigation use so it can only be obtained after successful application for special access, which requires one application per patient. Furthermore, depending on regions and funding policies, there is variation in the cost of lock solutions which determines the choice of the lock
solutions. It is not known which agent between taurolidine, EDTA or citrate is the most cost-effective. One case report provided cost-utility estimates on the use of taurolidine in a Canadian home PN patient suffering from multiple CRBSI episodes which demonstrated a huge spread in cost of using a lock solution vs. the standard of care (heparin) incurring repeated CRBSIs with cost overwhelmingly favoring prevention [28].

4. Conclusions

In conclusion, there are several non-antibiotic catheter lock solutions that can be used for antimicrobial prophylaxis, including citrate, ethanol, taurolidine, and tetrasodium EDTA. Although both ethanol and taurolidine have shown reduction in CRBSI rates in high-risk adult HPN patients (Table 1), there is limited evidence regarding the use of a catheter lock solution for primary prophylaxis of CRBSI. The Infectious Disease Society of America does recommend the use of antimicrobial catheter lock solutions for prophylaxis in high-risk patients with long-term catheters. However, one group from the Netherlands reports having placed their entire HPN population on the taurolidine lock solution [24].

Further research is needed to define which HPN patients should be placed on non-antibiotic antimicrobial catheter lock solution for prophylaxis and to determine which solution, or combination of solutions, is optimal. In the future, one might even consider adding glycercyl trinitrate to the catheter lock solution to add an antifungal protection [29].
Table 1. Studies of non-antibiotic antimicrobial catheter lock solutions in adult home parenteral nutrition (HPN) patients. CRBSI: catheter-related bloodstream infections.

| Authors (Year of Publication) | Study Design                | Number of Patients | Intervention                        | Location                      | Duration (Days Per Patient) | Outcome                                                                 | Complications | Notes                                                                 |
|-------------------------------|----------------------------|--------------------|-------------------------------------|-------------------------------|----------------------------|--------------------------------------------------------------------------|---------------|----------------------------------------------------------------------|
| Worley, M.V. et al. (2017)    | Retrospective cohort       | 24                 | 70% ethanol, usual care             | The United States             | 362, 235                   | 12.7 versus 2.4 CRBSIs per 1000 catheter days                           | None          | Ethanol use was instituted in April 2012. Patients compared before and after that date. |
| Davidson, J.B. et al. (2017)  | Retrospective cohort       | 8                  | 70% ethanol                         | The United States             | Not given                  | 4.18 versus 0.47 CRBSIs per 1000 catheter days                          | None          | Data not available individually for ethanol lock therapy.           |
| John, B.K. et al. (2012)      | Retrospective cohort       | 31                 | 70% ethanol, usual care             | The United States             | 878, 232                   | 3.53 versus 1.65 CRBSIs per 1000 catheter days                          | None          | Each patient served as their own control                             |
| Opilla, M.T. et al. (2007)    | Retrospective cohort       | 9                  | 25–70% ethanol, usual care          | The United States             | Not explicitly stated      | 8.3 versus 3.7 CRBSIs per 1000 catheter days                            | Some patients felt lightheaded and 'high' after flush. One patient felt nauseated. |                |
| Wouters, Y. et al. (2018)     | Randomized controlled trial| 105 randomized, 102 analyzed | 2% taurolidine, 0.9% saline          | Denmark, Israel, Italy, the Netherlands, the United Kingdom | 363, 346                   | 0.33 versus 1.44 CRBSIs per 1000 catheter days                          | No difference in rate of catheter occlusion or patient satisfaction |                |
| Tribler, S. et al. (2017)     | Randomized controlled trial| 41                 | 1.35% taurolidine + 4% citrate + heparin 100 IU/mL, heparin 100 IU/mL | Denmark                       | 481, 331                   | No CRBSIs in the taurolidine group versus seven CRBSIs in the heparin group (P-log-rank = 0.0034) | No difference in rate of mechanical complications | There were seven positive blood cultures in the taurolidine group but all were classified as contaminants and only one person received antibiotics for a short period |
| Bisseling, T.M. et al. (2010) | Open-label randomized controlled trial | 30                 | 2% taurolidine, heparin 150 IU/mL | The Netherlands               | 336, 353                   | 0.19 versus 233 CRBSIs per 1000 catheter days                          | None          |                                                                      |
Table 1. Cont.

| Authors (Year of Publication) | Study Design | Number of Patients | Intervention | Location | Duration (Days Per Patient) | Outcome | Complications | Notes |
|-------------------------------|--------------|--------------------|--------------|----------|-----------------------------|---------|---------------|-------|
| Klek, S. et al. (2014) [23]   | Open-label randomized controlled trial | 30 | 2% taurolidine, 1.35% taurolidine + citrate, 0.9% saline | Poland | 365.8, 365, 366 | 1 CRBSI in a patient using 1.35% taurolidine + citrate | 1 catheter occlusion in a patient using 2% taurolidine | This study was conducted in a group of patients with a low infection rate (0.3–0.4 episodes per patient per year) |
| Toure, A. et al. (2012) [20]  | Retrospective cohort | 15 | 1.35% taurolidine + 4% citrate, 0.9% saline | France | 365, 365 | 6.58 versus 1.09 CRBSIs per 1000 catheter days ($p < 0.001$) | Not available | Eight patients used taurolidine solution only once a week, the others used it after each PN infusion; each patient served as their own control using a before-and-after study design |
| Saunders et al. (2015) [15]  | Retrospective cohort | 22 | 1.35% taurolidine + 4% citrate or 2% taurolidine, 0.9% saline | The United Kingdom | 334, 351 | 5.71 versus 0.99 CRBSIs per 1000 catheter days ($p < 0.0001$) | Not available | Three out of 22 patients were using taurolidine for primary prophylaxis |
Author Contributions: J.N. and J.P.A. conceived the review. J.N. reviewed and selected clinical literature on the subject. B.J. and J.P.A. provided critical appraisal and revised the manuscript. All authors approved the final manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Raman, M.; Gramlich, L.; Whittaker, S.; Allard, J.P. Canadian home total parenteral nutrition registry: Preliminary data on the patient population. *Can. J. Gastroenterol.* 2007, 21, 643–648. [CrossRef] [PubMed]
2. Arechabala, M.C.; Catoni, M.I.; Claro, J.C.; Rojas, N.P.; Rubio, M.E.; Calvo, M.A.; Letelier, L.M. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis. *Cochrane Database Syst. Rev.* 2018, 4. [CrossRef] [PubMed]
3. Zhao, Y.; Li, Z.; Zhang, L.; Yang, J.; Yang, Y.; Tang, Y.; Fu, P. Citrate versus heparin lock for hemodialysis catheters: A systematic review and meta-analysis of randomized controlled trials. *Am. J. Kidney Dis.* 2014, 63, 479–490. [CrossRef] [PubMed]
4. Oltfoth, E.D.; Nijland, R.; Gülich, A.F.; Wanten, G.J. Microbiocidal effects of various taurolidine containing catheter lock solutions. *Clin. Nutr.* 2015, 34, 309–314. [CrossRef] [PubMed]
5. Weijmer, M.C.; van den Dorpel, M.A.; Van de Ven, P.J.; ter Wee, P.M.; van Geelen, J.A.; Groeneveld, J.O.; van Jaarsveld, B.C.; Koopmans, M.G.; le Poole, C.Y.; Schrander-Van der Meer, A.M.; et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. *J. Am. Soc. Nephrol.* 2005, 16, 2769–2777. [CrossRef] [PubMed]
6. Polaschegg, H.D.; Shah, C. Overspill of catheter locking solution: Safety and efficacy aspects. *ASAIO J.* 2003, 49, 713–715. [CrossRef] [PubMed]
7. Ash, S.R.; Mankus, R.A.; Sutton, J.M.; Criswell, R.E.; Crull, C.C.; Velasquez, K.A.; Smeltzer, B.D.; Ing, T.S. Concentrated Sodium Citrate (23%) for Catheter Lock. *Hemodial. Int.* 2000, 4, 22–31. [CrossRef] [PubMed]
8. Oliveira, C.; Nasr, A.; Brindle, M.; Wales, P.W. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: A meta-analysis. *Pediatrics* 2012, 129, 318–329. [CrossRef] [PubMed]
9. Rahhal, R.; Abu-El-Haija, M.A.; Fei, L.; Ebach, D.; Orkin, S.; Kiscaden, E.; Cole, C.R. Systematic Review and Meta-Analysis of the Utilization of Ethanol Locks in Pediatric Patients with Intestinal Failure. *JPEN. J. Parenter. Enteral Nutr.* 2018, 42, 690–690. [CrossRef] [PubMed]
10. John, B.K.; Khan, M.A.; Speerhas, R.; Rhoda, K.; Hamilton, C.; Dechicco, R.; Kirby, D.F. Ethanol lock therapy in reducing catheter-related bloodstream infections in adult home parenteral nutrition patients: Results of a retrospective study. *JPEN. J. Parenter. Enteral Nutr.* 2012, 36, 603–610. [CrossRef] [PubMed]
11. Davidson, J.B.; Edakkkanambeth Varayil, J.; Okano, A.; Whitaker, J.A.; Bonnes, S.L.; Kelly, D.G.; Hurt, R.T. Prevention of Subsequent Catheter-Related Bloodstream Infection Using Catheter Locks in High-Risk Patients Receiving Home Parenteral Nutrition. *JPEN J. Parenter. Enteral Nutr.* 2017, 41, 685–690. [CrossRef] [PubMed]
12. Mokha, J.S.; Davidovics, Z.H.; Samela, K.; Emerick, K. Effects of Ethanol Lock Therapy on Central Line Infections and Mechanical Problems in Children with Intestinal Failure. *JPEN J. Parenter. Enteral Nutr.* 2017, 41, 625–631. [CrossRef] [PubMed]
13. Abu-El-Haija, M.; Schultz, J.; Rahhal, R.M. Effects of 70% ethanol locks on rates of central line infection, thrombosis, breakage, and replacement in pediatric intestinal failure. *J. Pediatr. Gastroenterol. Nutr.* 2014, 58, 703–708. [CrossRef] [PubMed]
14. Bisseling, T.M.; Willems, M.C.; Versleijen, M.W.; Hendriks, J.C.; Vissers, R.K.; Wanten, G.J. Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: A heparin-controlled prospective trial. *Clin. Nutr.* 2010, 29, 464–468. [CrossRef] [PubMed]
15. Saunders, J.; Naghibi, M.; Leach, Z.; Parsons, C.; King, A.; Smith, T.; Stroud, M. Taurolidine locks significantly reduce the incidence of catheter-related blood stream infections in high-risk patients on home parenteral nutrition. *Eur. J. Clin. Nutr.* 2015, 69, 282–284. [CrossRef] [PubMed]
16. Al-Amin, A.H.; Sarveswaran, J.; Wood, J.M.; Burke, D.A.; Donnellan, C.F. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition. *J. Vasc. Access.* 2013, 14, 379–382. [CrossRef] [PubMed]
17. Jurewitsch, B.; Jeejeebhoy, K.N. Taurolidine lock: The key to prevention of recurrent catheter-related bloodstream infections. *Clin. Nutr.* 2005, 24, 462–465. [CrossRef] [PubMed]

18. Olthof, E.D.; Versleijen, M.W.; Huisman-de Waal, G.; Feuth, T.; Kievit, W.; Wanten, G.J. Taurolidine lock is superior to heparin lock in the prevention of catheter-related bloodstream infections and occlusions. *PLoS ONE* 2014, 9, e111216. [CrossRef] [PubMed]

19. Tribler, S.; Brandt, C.F.; Petersen, A.H.; Petersen, J.H.; Fuglsang, K.A.; Staun, M.; Jeppesen, P.B. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: A randomized, placebo-controlled trial. *Am. J. Clin. Nutr.* 2017, 106, 839–848. [CrossRef] [PubMed]

20. Touré, A.; Lauverjat, M.; Peraldi, C.; Boncompain-Gerard, M.; Gelas, P.; Barnoud, D.; Chambrier, C. Taurolidine lock solution in the secondary prevention of central venous catheter-associated bloodstream infection in home parenteral nutrition patients. *Clin. Nutr.* 2012, 31, 567–570. [CrossRef] [PubMed]

21. Wouters, Y.; Theilla, M.; Singer, P.; Tribler, S.; Jeppesen, P.B.; Pironi, L.; Wanten, G.J.A. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. *Aliment. Pharmacol. Ther.* 2018, 48, 410–422. [CrossRef] [PubMed]

22. Liu, H.; Deng, J.; Chen, L.; Yuan, L.; Wu, Y. Preventing catheter-related bacteremia with taurolidine-citrate catheter locks: A systematic review and meta-analysis. *Blood Purif.* 2014, 37, 179–187. [CrossRef] [PubMed]

23. Klek, S.; Szczepanek, K.; Hermanowicz, A.; Galas, A. Taurolidine lock in home parenteral nutrition in adults: Results from an open-label randomized controlled trial. *JPEN J. Parenter. Enteral Nutr.* 2015, 39, 331–335. [CrossRef] [PubMed]

24. Olthof, E.D.; Rentenaar, R.J.; Rijks, A.J.; Wanten, G.J. Absence of microbial adaptation to taurolidine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use taurolidine locks. *Clin. Nutr.* 2013, 32, 538–542. [CrossRef] [PubMed]

25. Percival, S.; Kite, P.; Eastwood, K.; Murga, R.; Carr, J.; Arduino, M.; Donlan, R.M. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. *Infect. Control Hosp. Epidemiol.* 2005, 26, 515–519. [CrossRef] [PubMed]

26. Kanaa, M.; Wright, M.J.; Akhani, H.; Laboi, P.; Bhandari, S.; Sandoe, J.A. Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial. *Am. J. Kidney Dis.* 2015, 66, 1015–1023. [CrossRef] [PubMed]

27. Banfi, G.; Salvagno, G.L.; Lippi, G. The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. *Clin. Chem. Lab Med.* 2007, 45, 565–576. [CrossRef] [PubMed]

28. Jurewitsch, B.; Lee, T.; Park, J.; Jeejeebhoy, K. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. *JPEN J. Parenter. Enteral Nutr.* 1998, 22, 242–244. [CrossRef] [PubMed]

29. Rosenblatt, J.; Reitzel, R.; Dvorak, T.; Jiang, Y.; Hachem, R.Y.; Raad, I.I. Glycerol trinitrate complements citrate and ethanol in a novel antimicrobial catheter lock solution to eradicate biofilm organisms. *Antimicrob. Agents Chemother.* 2013, 57, 3555–3560. [CrossRef] [PubMed]

30. Worley, M.V.; Dollard, E.W.; Aragon, L.; Henderson, K.; Abbo, L.M.; Byers, P. Role of Ethanol Locks in Reducing Bloodstream Infections in Adults on Parenteral Nutrition. *Infect. Control Hosp. Epidemiol.* 2017, 38, 1133–1135. [CrossRef] [PubMed]

31. Opilla, M.T.; Kirby, D.F.; Edmond, M.B. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. *JPEN J. Parenter. Enteral Nutr.* 2007, 31, 302–305. [CrossRef] [PubMed]